The New Developing Treatment of Parkinson’s Disease

Parkinson’s disease (PD) is the second most common neurodegenerative illness that affects the central nervous system, especially the motor nervous system and it is marked clinically by movement impairment. Its symptoms usually arise gradually over time. Tremors, limb stiffness and abnormal gait are...

Full description

Bibliographic Details
Main Author: You Hanlin
Format: Article
Language:English
Published: EDP Sciences 2022-01-01
Series:SHS Web of Conferences
Online Access:https://www.shs-conferences.org/articles/shsconf/pdf/2022/14/shsconf_stehf2022_01017.pdf
Description
Summary:Parkinson’s disease (PD) is the second most common neurodegenerative illness that affects the central nervous system, especially the motor nervous system and it is marked clinically by movement impairment. Its symptoms usually arise gradually over time. Tremors, limb stiffness and abnormal gait are all obvious in the early phase, and some PD patients also have non-motor symptoms like behavioral problems. Besides, decline of cognition is common in severely ill patients. While the pathogenesis of PD has not been fully studied, genetic and environmental factors are generally thought to play a role. There are a lot of potential mechanisms like mitochondrial dysfunction, neuroinflammation and abnormal metabolism. Drugs therapy is the major treatment for PD. But drugs may bring some side effects, it is urgent to find new treatment targeting at specific sites. This review introduces the current drugs and new developing drugs for PD.
ISSN:2261-2424